Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Epitalon (AEDG, synthetic analog of Epithalamin)
Epitalon is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Khavinson as an analog of the bovine pineal extract Epithalamin. It is a research-only bioregulator — not FDA-approved — investigated for claimed telomerase activation and circadian/melatonin effects, with evidence limited primarily to Khavinson-group studies.
Khavinson-group in vitro studies claim upregulation of telomerase activity / hTERT expression in cultured human somatic cells, with modulation of pineal melatonin secretion and circadian/age-related gene-expression markers. These mechanism claims have not been consistently replicated outside the originating research group.
The evidence base is dominated by Khavinson-group publications. A 2003 Bulletin of Experimental Biology and Medicine paper reported telomerase activation and telomere elongation in cultured human somatic cells. Open-label and small-cohort studies in elderly Russian patients have reported reduced mortality over 6–12 year follow-up and normalization of melatonin rhythms, but these trials have significant methodological limitations (open-label, single-center, limited controls) and have not been independently replicated in rigorous Western controlled trials. No Phase 2/3 trials, no FDA approval.
Typical Dose
5mg
Range
5-10mg
Frequency
1x/day (subcutaneous)
Route
SubQ
Duration
10-20 day cycles, 1-2x/year
Reconstitution
10mg vial + 2mL bacteriostatic water = 5,000mcg/mL
Notes
Grey-market dosing only — not clinically validated for any endpoint. Commonly reported as 5–10 mg SubQ daily for 10–20 day cycles, repeated 1–2 times per year.
Aggregated from 69 lab-verified Certificates of Analysis uploaded directly by 1 verified lab. Purity averages exclude values outside [50%, 100%] to filter unit-misreads.
COAs
69
Verified labs
1
Avg purity
99.32%
±1.68%
Endotoxin tested
48%
Tested by
These biomarkers are commonly tracked to assess response and safety. Run baseline labs before starting, mid-cycle labs halfway through, and post-cycle labs 1–2 weeks after the final dose.
This platform provides informational tools only, not medical advice. This information is for educational purposes only. Consult a licensed provider.